PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES
申请人:Novartis AG
公开号:EP1423391A1
公开(公告)日:2004-06-02
[EN] PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES<br/>[FR] PYRROLOPYRIMIDES EN TANT QU'AGENTS D'INHIBITION DE CYSTEINE PROTEASES
申请人:NOVARTIS AG
公开号:WO2003020721A1
公开(公告)日:2003-03-13
The invention provides compounds of Formula I or a pharmaceutically acceptable salt or ester thereof wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors.
[EN] PYRROLOQUINOLINONE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS<br/>[FR] DÉRIVÉS DE PYRROLOQUINOLINONE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
申请人:WYETH CORP
公开号:WO2007053352A2
公开(公告)日:2007-05-10
[EN] The present invention provides a compound of formula (I) and the use thereof in the therapeutic treatment of a central nervous system disorder related to or affected by the 5-HT6 receptor. [FR] La présente invention concerne un composé de formule (I) et l'emploi de ce composé dans le traitement thérapeutique d'un trouble du système nerveux central lié à ou affecté par le récepteur 5-HT6.